Insulet has launched its Omnipod 5 automated insulin delivery system (Omnipod 5) in the UK.

Omnipod 5 is indicated for use in type 1 diabetes patients aged two years and above.

It can integrate with a continuous glucose monitor to manage blood sugar without multiple daily injections and zero finger sticks.

The device is claimed to be the first CE-marked tubeless hybrid closed loop system that can be integrated with the Dexcom G6 Continuous Glucose Monitoring (CGM) System for adjusting insulin delivery automatically, offering protection against high and low levels of glucose.

It includes a tubeless pod that is enhanced with SmartAdjust technology along with the Omnipod 5 Controller with its integrated SmartBolus Calculator.

The SmartAdjust technology receives a CGM value and trend every five minutes and predicts where the glucose level of the user will be in the next 60 minutes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Using this information, the Omnipod 5 system increases, decreases or pauses the delivery of insulin based on the patient’s desired and customised glucose target.

The company stated that the device simplifies the daily management of diabetes.

Insulet president and CEO Jim Hollingshead said: “Since its commercial launch in the United States, Omnipod 5 has had a remarkable impact on people with diabetes.

“Every day, we hear how this revolutionary experience of Omnipod 5 reduces the burden and improves the quality of life for people with diabetes and we are excited to make a difference in other parts of the world, beginning with the UK.

“We are committed to making Omnipod 5 an option for as many people as possible, as quickly as we can and working hard to secure broad access globally.”

Furthermore, the company intends to launch Omnipod 5 in Germany later this year.

In April this year, it received approval from the US Food and Drug Administration for the Omnipod GO basal-only insulin pod for use in individuals with type 2 diabetes aged 18 and above.